Active Biotech AB (publ) (ACTI.ST)
- Previous Close
0.5590 - Open
0.5610 - Bid 0.5310 x --
- Ask 0.5500 x --
- Day's Range
0.5300 - 0.5780 - 52 Week Range
0.4005 - 1.4780 - Volume
207,044 - Avg. Volume
626,792 - Market Cap (intraday)
198.956M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1700 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.70
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
www.activebiotech.comRelated News
Performance Overview: ACTI.ST
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACTI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACTI.ST
Valuation Measures
Market Cap
202.21M
Enterprise Value
170.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.05%
Return on Equity (ttm)
-140.47%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-45.8M
Diluted EPS (ttm)
-0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
36.2M
Total Debt/Equity (mrq)
9.77%
Levered Free Cash Flow (ttm)
-27.53M
Research Analysis: ACTI.ST
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: ACTI.ST
ACTI.ST does not have Company Insights